ProCE Banner Activity

Menin Inhibition in Acute MLL Rearranged Leukemias: A New Target for Precision Care

Slideset Download
Review this slideset on menin inhibitors in MLLr/mNPM1 acute leukemias.

Released: October 17, 2022

Expiration: October 16, 2023

Share

Faculty

Eytan M. Stein

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Syndax

Faculty Disclosure

Primary Author

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Eytan M. Stein, MD: consultant/advisor/speaker: Agios, Astellas, Celgene, Daiichi, Genentech, PTC Therapeutics, Syros; ownership interests: Auron.